Table 1 Demographic and clinical characteristics of 100 early- or intermediate-stage HCC patients who received surgical resection, LT, or locoregional therapies
Characteristics | Training Set n = 49 | Validation Set n = 51 | P value |
|---|---|---|---|
Age, median (IQR) | 67(59–74) | 66(62–70.5) | 0.95 |
Male, n (%) | 33(67.3%) | 33(64.7%) | 0.78 |
Post-Tx status | Â | Â | 0.94 |
 Viable | 33(67.3%) | 34(66.7%) |  |
 Nonviable | 16(32.7%) | 17(33.3%) |  |
Race/ethnicity, n (%) | Â | Â | 0.27 |
 Asian | 11(22.4%) | 7(13.7%) |  |
 Black | 5(10.2%) | 1(2.0%) |  |
 White | 12(24.5%) | 16(31.4%) |  |
 Hispanic | 20(40.8%) | 23(45.1%) |  |
 Others/Unknown | 1(2.1%) | 4(7.8%) |  |
Cirrhosis, n (%) | 40 (81.6%) | 47(92.2%) | 0.12 |
HCC etiology, n (%) | Â | Â | 0.04 |
 HBV | 7(14.2%) | 2(3.9%) |  |
 HCV | 9(18.4%) | 19(37.3%) |  |
 ALD | 9(18.4%) | 7(13.7%) |  |
 MASLD | 15(30.6%) | 16(31.4%) |  |
 ≥ 2 etiologies | 0(0%) | 3(5.9%) |  |
 Others | 9(18.4%) | 4(7.8%) |  |
BCLC stage, n (%) | Â | Â | 0.72 |
 Stage 0 | 2(4.1%) | 6(11.8%) |  |
 Stage A | 40(81.6%) | 36(70.6%) |  |
 Stage B | 7(14.3%) | 9(17.6%) |  |
Tx option | Â | Â | 0.52 |
 Resection | 5(10.2%) | 3(5.9%) |  |
 LT | 0(0%) | 1(2.0%) |  |
 Local ablation | 14(28.5%) | 17(33.3%) |  |
 TACE | 9(18.4%) | 14(27.5%) |  |
 TARE | 21(42.9%) | 17(33.3%) |  |
Milan criteria, n (%) | Â | Â | Â |
 Within Milan criteria | 36 (73.5%) | 43(84.3%) | 0.18 |
 Outside Milan criteria | 13 (26.5%) | 8(15.7%) |  |
AFP, ng/mL, median (IQR) | 10.1 (3.4–91.8) | 9.2(3.6–23.4) | 0.26 |